Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial) study protocol for a nationwide multicenter randomized controlled trial

Janssen, Q.P.; Dam, J.L. van; Bonsing, B.A.; Bos, H.; Bosscha, K.P.; Coene, P.P.L.O.; ... ; Dutch Pancreatic Canc Grp (2021)

Article / Letter to editor

Background Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.MethodsThis nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and <= 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as <= 90 degrees arterial and <= 270 degrees venous involvement without occlusion. Patients receive 8cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36Gy in 15 fractions) during the second cycle, followed by surgery and 4cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients assuming an accrual period of 3years and 1.5years follow-up.DiscussionThe PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer.Trial registrationPrimary registry and trial identifying number: EudraCT: 2017-002036-17.Date of registration: March 6, 2018.Secondary identifying numbers: The Netherlands National Trial Register - NL7094, NL61961.078.17, MEC-2018-004.

• Neoadjuvant
• FOLFIRINOX
• Gemcitabine
• Chemoradiotherapy
• Localized pancreatic cancer
• Intention-to-treat
• Randomized controlled trial
• Overall survival
• Quality of life

• All authors: Janssen, Q.P.; Dam, J.L. van; Bonsing, B.A.; Bos, H.; Bosscha, K.P.; Coene, P.P.L.O.; Eijck, C.H.J. van; Hingh, I.H.J.T. de; Karsten, T.M.; Kolk, M.B. van der; Patijn, G.A.; Liem, M.S.L.; Santvoort, H.C. van; Loosveld, O.J.L.; Vos-Geelen, J. de; Zonderhuis, B.M.; Homs, M.Y.V.; Tienhoven, G. van; Besselink, M.G.; Wilmink, J.W.; Koerkamp, B.G.; Dutch Pancreatic Canc Grp
• Date: 2021-03-23
• Journal: BMC Cancer
• Volume: 21
• Issue: 1
• DOI: doi:10.1186/s12885-021-08031-z
• Link: https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08031-z